Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling.
While adipose tissue-associated macrophages contribute to development of chronic inflammation and insulin resistance of obesity, little is known about the role of hepatic Kupffer cells in this environment. Here we address the impact of Kupffer cell ablation using clodronate-encapsulated liposome depletion in a diet-induced obese (DIO) and insulin resistant mouse model. Hepatic expression of macrophage markers measured by realtime RT-PCR remained unaltered in DIO mice despite characteristic expansion of adipose tissue-associated macrophages. DIO mouse livers displayed increased expression of alternative activation markers but unaltered proinflammatory cytokine expression when compared to lean mice. Kupffer cell ablation reduced hepatic anti-inflammatory cytokine IL-10 mRNA expression in lean and DIO mice by 95% and 84%, respectively. Despite decreased hepatic IL-6 gene expression after ablation in lean and DIO mice, hepatic STAT3 phosphorylation, Socs3 and acute phase protein mRNA expression increased. Kupffer cell ablation in DIO mice resulted in additional hepatic triglyceride accumulation and a 30-40% reduction in hepatic insulin receptor autophosphorylation and Akt activation. Implicating systemic loss of IL-10, high-fat-fed IL-10 knockout mice also displayed increased hepatic STAT3 signaling and hepatic triglyceride accumulation. Insulin signaling was not altered, however. In conclusion, Kupffer cells are a major source of hepatic IL-10 expression, the loss of which is associated with increased STAT3-dependent signaling and steatosis. One or more additional factors appear to be required, however, for the Kupffer cell-dependent protective effect on insulin receptor signaling in DIO mice.
Clementi
Alicia H
AH
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14642, USA.
Gaudy
Allison M
AM
van Rooijen
Nico
N
Pierce
Robert H
RH
Mooney
Robert A
RA
D000273:Adipose Tissue / Q000378:metabolism / Q000473:pathology; D000818:Animals; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000494:pharmacology; D004002:Clodronic Acid / Q000009:adverse effects / Q000494:pharmacology; D004032:Diet / Q000009:adverse effects*; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects; D018836:Inflammation Mediators / Q000378:metabolism; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D016753:Interleukin-10 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007728:Kupffer Cells / Q000378:metabolism* / Q000473:pathology; D008081:Liposomes; D008264:Macrophages / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D009765:Obesity / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D012333:RNA, Messenger; D011972:Receptor, Insulin / Q000378:metabolism; D050796:STAT3 Transcription Factor / Q000378:metabolism*; D015398:Signal Transduction; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism
D050071:Bone Density Conservation Agents; D018836:Inflammation Mediators; D007328:Insulin; D015850:Interleukin-6; D008081:Liposomes; D012333:RNA, Messenger; D050796:STAT3 Transcription Factor; C491411:Socs3 protein, mouse; C494087:Stat3 protein, mouse; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins; D014280:Triglycerides; D004002:Clodronic Acid; D016753:Interleukin-10; D011972:Receptor, Insulin; D051057:Proto-Oncogene Proteins c-akt
Science. 2004 Oct 15;306(5695):457-61
15486293
Med Microbiol Immunol. 2006 Dec;195(4):173-83
16741736
J Immunol. 1992 Sep 15;149(6):2021-7
1381393
Endocrinology. 2005 Aug;146(8):3417-27
15845623
Endocrinology. 2006 Oct;147(10):4553-8
16709607
J Hepatol. 2008 Apr;48(4):628-37
18267346
Metabolism. 1996 Sep;45(9):1080-8
8781294
J Clin Endocrinol Metab. 2002 May;87(5):2084-9
11994345
Biochem Biophys Res Commun. 2009 Jul 31;385(3):351-6
19463788
Immunol Cell Biol. 2002 Dec;80(6):550-7
12406389
Cell Biochem Funct. 2004 Sep-Oct;22(5):327-32
15338473
Hepatology. 1996 May;23(5):1239-43
8621159
Expert Opin Investig Drugs. 2007 Mar;16(3):291-302
17302524
Nat Med. 2005 Feb;11(2):183-90
15685173
Science. 1996 Feb 2;271(5249):665-8
8571133
Diabetes. 2008 Jun;57(6):1470-81
18305141
Hypertension. 2009 Mar;53(3):508-15
19171794
J Clin Invest. 2007 Jan;117(1):175-84
17200717
Arch Histol Cytol. 2002 Aug;65(3):251-61
12389664
Hepatology. 2005 Oct;42(4):880-5
16175608
J Biol Chem. 2003 Nov 21;278(47):46654-60
13129912
J Clin Invest. 1997 Dec 1;100(11):2900-8
9389757
J Clin Invest. 2003 Dec;112(12):1821-30
14679177
Nat Rev Immunol. 2003 Jan;3(1):23-35
12511873
Diabetes. 2002 Dec;51(12):3391-9
12453891
J Biol Chem. 2003 Jan 3;278(1):661-71
12403768
Cell Metab. 2008 Jun;7(6):485-95
18522830
Circulation. 2004 Sep 21;110(12):1564-71
15364812
Toxicol Pathol. 2005;33(1):52-62
15805056
Liver Transpl. 2003 May;9(5):489-97
12740792
J Clin Invest. 1995 May;95(5):2111-9
7738178
Science. 1997 Dec 5;278(5344):1803-5
9388184
J Lipid Res. 2009 Feb;50(2):214-24
18772483
Trends Cell Biol. 2001 Sep;11(9):372-7
11514191
Diabetes. 2008 Jun;57(6):1526-35
18375438
Diabetes. 2002 Apr;51(4):1088-92
11916930
Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2195-201
18818420
Diabetes. 2005 Dec;54(12):3458-65
16306362
Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51
11287357
J Leukoc Biol. 2002 Jul;72(1):154-62
12101275
Diabetes. 1999 Jun;48(6):1270-4
10342815
Shock. 2003 Aug;20(2):116-22
12865654
Diabetes. 2007 Jan;56(1):16-23
17192460
J Clin Invest. 1996 Aug 15;98(4):1010-20
8770874
Science. 1993 Jan 1;259(5091):87-91
7678183
Curr Opin Crit Care. 2001 Apr;7(2):99-104
11373518
Diabetes. 2004 Apr;53(4):1060-7
15047622
Hepatology. 2003 Nov;38(5):1188-98
14578857
J Biol Chem. 2002 Nov 1;277(44):42394-8
12228220
Br J Nutr. 2004 Sep;92(3):347-55
15469638
J Biol Chem. 2004 Aug 13;279(33):34733-40
15181014
Nature. 2006 Apr 13;440(7086):944-8
16612386
J Immunol. 2000 Jun 15;164(12):6166-73
10843666
J Immunol Methods. 1994 Sep 14;174(1-2):83-93
8083541
Nature. 2007 Jun 28;447(7148):1116-20
17515919
J Clin Invest. 2006 Jun;116(6):1494-505
16691291
Int J Immunopharmacol. 2000 Dec;22(12):1131-5
11137620
Toxicol Appl Pharmacol. 2001 Jan 1;170(1):39-45
11141354
Nature. 2002 Nov 21;420(6913):333-6
12447443
Toxicol Pathol. 1997 May-Jun;25(3):245-55
9210255
J Clin Invest. 1994 Oct;94(4):1543-9
7523453
Diabetes Care. 2001 Feb;24(2):362-5
11213893
J Biol Chem. 2003 Apr 18;278(16):13740-6
12560330
J Clin Invest. 2003 Dec;112(12):1796-808
14679176
J Clin Invest. 2006 Jan;116(1):115-24
16341265
BMC Genomics. 2005 Sep 28;6:137
16191192
Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):1032-9
15998258
Cell Metab. 2008 Jun;7(6):496-507
18522831
Annu Rev Biochem. 2007;76:141-65
17362201
J Leukoc Biol. 2003 Feb;73(2):209-12
12554797